A5012591468- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Renal Transplantation Outcomes and Treatments
- Organ Donation and Transplantation
- Lung Cancer Treatments and Mutations
- Lipoproteins and Cardiovascular Health
- Cancer Immunotherapy and Biomarkers
- Renal and Vascular Pathologies
- Esophageal Cancer Research and Treatment
- Colorectal Cancer Treatments and Studies
- Bladder and Urothelial Cancer Treatments
- Renal cell carcinoma treatment
- Venous Thromboembolism Diagnosis and Management
- Transplantation: Methods and Outcomes
- Organ Transplantation Techniques and Outcomes
- Pancreatic and Hepatic Oncology Research
- Antiplatelet Therapy and Cardiovascular Diseases
- Coronary Artery Anomalies
- Congenital heart defects research
- Congenital Heart Disease Studies
- Gastric Cancer Management and Outcomes
Natera (United States)
2017-2023
Harvard University Press
2014
Stanford University
2012-2014
University of Pittsburgh Medical Center
2014
Harvard University
2014
San Francisco General Hospital
2014
University of California, San Francisco
2014
VA Palo Alto Health Care System
2014
Veterans Health Administration
2012
Standard noninvasive methods for detecting renal allograft rejection and injury have poor sensitivity specificity. Plasma donor-derived cell-free DNA (dd-cfDNA) has been reported to accurately detect in transplant recipients shown discriminate from stable organ function kidney recipients. This study used a novel single nucleotide polymorphism (SNP)-based massively multiplexed PCR (mmPCR) methodology measure dd-cfDNA various types of the detection rejection/injury without prior knowledge...
PURPOSE More than 50% of patients with stage IV colorectal cancer (metastatic [mCRC]) relapse postresection. The efficacy postoperative systemic treatment is limited in this setting. Thus, these would greatly benefit from the use a reliable prognostic biomarker, such as circulating tumor DNA (ctDNA) to identify minimal or molecular residual disease (MRD). PATIENTS AND METHODS We analyzed cohort 112 mCRC who had undergone metastatic resection curative intent part PREDATOR clinical trial....
The choice of antiplatelet therapy after acute coronary syndrome (ACS) is complicated: Ticagrelor and prasugrel are novel alternatives to clopidogrel, patients with some genotypes may not respond low-cost generic formulations clopidogrel available.To determine the most cost-effective strategy for dual percutaneous intervention ACS.Decision-analytic model.Published literature, Medicare claims, life tables.Patients having ACS.Lifetime.Societal.Five strategies were examined: prasugrel,...
Circulating tumor DNA (ctDNA) analyses allow for postoperative risk stratification in patients with curatively treated colon and breast cancers. Use of ctDNA esophagogastric cancers (EGC) is less characterized could identify high-risk who have been curative intent.In this retrospective analysis real-world data, levels were analyzed the preoperative, postoperative, surveillance settings EGC using a personalized multiplex polymerase chain reaction-based next-generation sequencing assay. Plasma...
Abstract Purpose: Chemoimmunotherapy (chemoIO) is a prevalent first-line treatment for advanced driver-negative non–small cell lung cancer (NSCLC), with maintenance therapy given after induction. However, there significant clinical variability in the duration, dosing, and timing of induction chemoIO. We used circulating tumor DNA (ctDNA) monitoring to inform outcomes patients NSCLC receiving Experimental Design: This retrospective study included 221 from phase III trial...
Introduction Colorectal cancer (CRC) is a highly prevalent disease, wherein, ~30%–40% of patients with CRC relapse postresection. In some CRC, adjuvant chemotherapy can help delay recurrence or be curative. However, current biomarkers show limited clinical utility in determining if/when should administered, to provide benefit. Circulating tumour DNA (ctDNA) measure molecular residual disease (MRD) and high specificity sensitivity. This study protocol investigates the ctDNA for optimal use...
Several studies have demonstrated the prognostic value of circulating tumor DNA (ctDNA); however, correlation mean molecules (MTM)/ml plasma and variant allele frequency (mVAF; %) with clinical parameters is yet to be understood. In this study, we analyzed ctDNA data in a pan-cancer cohort 23 543 patients who had testing performed using personalized, tumor-informed assay (Signatera™, mPCR-NGS assay). For ctDNA-positive patients, between MTM/ml mVAF was examined. Two subanalyses were...
Abstract Background The 22q11.2 deletion syndrome is a variably expressed disorder that can include cardiac, palate, and other physical abnormalities, immunodeficiency, hypocalcemia. Because of the extreme variability in phenotype, there has been no available estimate total medical expenditure associated with average case. Methods We have developed model to cost from time diagnosis age 20. Costs were based on patients seen at specialty center but also considered those components care...
The clinical utility of early detection and treatment allograft rejection is well-established. Despite frequent testing called for by standard care protocols, the five-year kidney survival rate estimated to be as low 71%. Herein, we report on posttransplant provided recipients board-certified nephrologists in United States. We measured practice a representative sample 175 practicing nephrologists. All providers cared simulated patients' status after renal transplant ranging from 30-75 years...
Introduction Plasma donor-derived cell-free DNA (dd-cfDNA) has been implicated as a noninvasive marker for transplant (tx) rejection. dd-cfDNA evaluation requires differentiation of donor/recipient by sequencing; recent studies have amplified hundreds target SNPs to detect active rejection in kidney allografts with 59.3% sensitivity and 84.7% specificity. We measure thousands informative assess high accuracy selected cohort tx patients having contemporaneous biopsies scored presence type...
9075 Background: Chemoimmunotherapy (ChemoIO) is a prevalent first-line treatment for advanced NSCLC without driver mutations, with maintenance therapy recommended after induction. However, real-world data suggests variability in therapy’s timing, intensity, and duration. Motivated by evidence that ctDNA monitoring can predict outcomes pts receiving IO cancers, we hypothesized could inform prior to the start of therapy. Methods: This retrospective study included 98 from completed phase III...
Abstract Minimally invasive methods for assessment of tumor burden, early detection disease relapse and monitoring therapeutic efficacy are needed to improve individualized follow-up treatment patients diagnosed with bladder cancer. The ability predict pathologic complete response after neoadjuvant chemotherapy (NAC) through ctDNA in plasma may enable strategies preservation. aim the study was use patient-specific mutations identify residual disease, metastatic monitor longitudinally...
Abstract Personalized and tumor-informed, circulating tumor DNA (ctDNA) analysis allows for postoperative risk stratification in patients with curatively treated esophagogastric cancers (EGC). In this retrospective of real-world data, ctDNA levels were analyzed 295 EGC using a personalized multiplex PCR-based next generation sequencing assay. Postoperative was significantly associated shorter recurrence-free survival. multivariate analyses, status the most significant prognostic factor...